This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davalli, A. M. Articles by Secchi, A. Search for Related Content PubMed PubMed Citation Articles by Davalli, A. M. Articles by Secchi, A.

Insights from a Successful Case of Intrahepatic Islet Transplantation into a Type 1 Diabetic Patient

Cattedra di Clinica Medica, Università Vita-Salute, Ospedale San Raffaele (A.M.D., P.M., L.F., G.P.); Departments of Pathology (F.S., M.F.) and Surgery (C.S., F.B., V.D.C.), Istituto Scientifico San Raffaele; and University of Milan (A.S.), 20132 Milan, Italy

Address all correspondence and requests for reprints to: Dr. Alberto M. Davalli, Cattedra di Clinica Medica, Università Vita-Salute, Hospital San Raffaele, Via Olgettina 60, 20132 Milan, Italy. E-mail: alberto.davalli{at}hsr.it

We report a case of long-term (>4 yr) successful intrahepatic islet transplantation into a type 1 diabetic patient chronically immunosuppressed for a prior kidney graft. The exogenous insulin requirement decreased progressively after transplantation, and insulin treatment was withdrawn at 6 months. Glycosylated hemoglobin levels were in the normal range at 1 and 2 yr (5.3%) and increased slightly above the upper normal limit at 3 and 4 yr (6.3% and 6.4%). Fasting C peptide levels remained stable during the entire follow-up, but the proinsulin to insulin ratios increased dramatically at yr 3. Glycemic levels after an oral glucose tolerance test showed a diabetic profile at 1 yr, a normal profile at 2 yr, and an impaired glucose tolerance profile at 3 yr. Intravenous glucose tolerance test-induced first phase insulin release, present at 1 and 2 yr, disappeared at 3 yr. Diabetes-related autoantibodies (islet cell antibodies, glutamic acid decarboxylase antibodies, and tyrosine phosphatase-like protein antibodies) were undetectable before transplantation and remained so during the entire follow-up. The patient died of myocardial infarction 50 months after transplantation while she was still in good metabolic control (glycosylated hemoglobin, <6.8%) in the absence of exogenous insulin administration. The autoptic liver showed well granulated islets, richly vascularized and without evidence of lympho-mononuclear cell infiltration. The morphometrically extrapolated intrahepatic ß-cell mass was 99.9 mg. In conclusion, this successful islet graft showed a bell-shaped clinical effect, maximal at 2 yr after transplantation, followed by a slow progressive decline. The absence of allo- and autoreactivities against the transplanted islets points to a nonimmune-mediated ß-cell loss as the cause of graft functional deterioration.

This article has been cited by other articles:

				M.-C. Vantyghem, J. Kerr-Conte, L. Arnalsteen, G. Sergent, F. Defrance, V. Gmyr, N. Declerck, V. Raverdy, B. Vandewalle, P. Pigny, et al. Primary Graft Function, Metabolic Control, and Graft Survival After Islet Transplantation Diabetes Care, August 1, 2009; 32(8): 1473 - 1478. [Abstract] [Full Text] [PDF]

				F. Bertuzzi and C. Ricordi Prediction of Clinical Outcome in Islet Allotransplantation Diabetes Care, February 1, 2007; 30(2): 410 - 417. [Full Text] [PDF]

				P. Fiorina, C. Gremizzi, P. Maffi, R. Caldara, D. Tavano, L. Monti, C. Socci, F. Folli, F. Fazio, E. Astorri, et al. Islet Transplantation Is Associated With an Improvement of Cardiovascular Function in Type 1 Diabetic Kidney Transplant Patients Diabetes Care, June 1, 2005; 28(6): 1358 - 1365. [Abstract] [Full Text] [PDF]

				M. Venturini, E. Angeli, P. Maffi, P. Fiorina, F. Bertuzzi, M. Salvioni, F. De Cobelli, C. Socci, L. Aldrighetti, C. Losio, et al. Technique, Complications, and Therapeutic Efficacy of Percutaneous Transplantation of Human Pancreatic Islet Cells in Type 1 Diabetes: The Role of US Radiology, February 1, 2005; 234(2): 617 - 624. [Abstract] [Full Text] [PDF]

				E. A. Ryan, J. R.T. Lakey, B. W. Paty, S. Imes, G. S. Korbutt, N. M. Kneteman, D. Bigam, R. V. Rajotte, and A.M. J. Shapiro Successful Islet Transplantation: Continued Insulin Reserve Provides Long-Term Glycemic Control Diabetes, July 1, 2002; 51(7): 2148 - 2157. [Abstract] [Full Text] [PDF]

				B. Ritz-Laser, J. Oberholzer, C. Toso, M.-C. Brulhart, K. Zakrzewska, F. Ris, P. Bucher, P. Morel, and J. Philippe Molecular Detection of Circulating {beta}-Cells After Islet Transplantation Diabetes, March 1, 2002; 51(3): 557 - 561. [Abstract] [Full Text] [PDF]